Zyloprim

Hyperuricemia, Lesch-Nyhan Syndrome, Chemotherapy + 15 more

Treatment

16 FDA approvals

20 Active Studies for Zyloprim

What is Zyloprim

Allopurinol

The Generic name of this drug

Treatment Summary

Gout is a painful condition caused by a buildup of uric acid crystals around the joints. It has been known since ancient times, and is mentioned in the biographies of several famous people. Allopurinol is a medication that is commonly used to treat gout. It works by reducing the levels of uric acid in the body and was first approved by the FDA in 1966. It is now made by multiple pharmaceutical companies.

Zyloprim

is the brand name

image of different drug pills on a surface

Zyloprim Overview & Background

Brand Name

Generic Name

First FDA Approval

How many FDA approvals?

Zyloprim

Allopurinol

1966

270

Approved as Treatment by the FDA

Allopurinol, also called Zyloprim, is approved by the FDA for 16 uses such as female patients with daily uric acid excretion that exceeds 750 mg/day and Cancer .

female patients with daily uric acid excretion that exceeds 750 mg/day

Cancer

Kidney Calculi

Hyperuricemia

Leukemias

Malignant Lymphomas

Arthritis, Gouty

Used to treat Gouty Arthritis in combination with Lesinurad

failed previous allopurinol monotherapy

Used to treat failed previous allopurinol monotherapy in combination with Lesinurad

Hyperuricemia

Hyperuricemia

Chemotherapy

Lymphoma, Non-Hodgkin

Leukemia

Symptomatic

Secondary gout

Primary Gout

Effectiveness

How Zyloprim Affects Patients

Allopurinol is a drug that helps to reduce the amount of uric acid in the body. This can help to relieve symptoms of gout, such as joint pain, swelling, inflammation, and stiffness.

How Zyloprim works in the body

Allopurinol is a medication that works to reduce the symptoms of gout. It does this by blocking an enzyme called xanthine oxidase, which converts hypoxanthine to xanthine and then to uric acid. This blocks the body from making too much uric acid, which can cause gout. Allopurinol also increases the reutilization of hypoxanthine and xanthine for making nucleotides, further reducing the levels of uric acid. As a result, this medication lowers the levels of uric acid in the blood, preventing gout symptoms, and encourages the dissolution

When to interrupt dosage

The recommended dosage of Zyloprim is contingent upon the determined condition, such as Gout Flares, Leukemias and Cancer. The measure of dosage varies, depending on the technique of delivery (e.g. Injection, powder, lyophilized, for solution - Intravenous or Tablet, film coated - Oral) displayed in the table beneath.

Condition

Dosage

Administration

Symptomatic

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Chemotherapy

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Chronic Kidney Disease (CKD)

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Metabolic Diseases

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Gout Flares

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Eczema

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Leukemia

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Primary Gout

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Hyperuricemia

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Lesch-Nyhan Syndrome

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Arthritis, Gouty

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Kidney Calculi

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

female patients with daily uric acid excretion that exceeds 750 mg/day

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

failed previous allopurinol monotherapy

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Hyperuricemia

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Urinary Bladder Calculi (disorder)

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Lymphoma, Non-Hodgkin

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Secondary gout

, 300.0 mg, 100.0 mg, 50.0 mg/mL, 200.0 mg

, Tablet, Oral, Tablet - Oral, Tablet, coated - Oral, Tablet, coated, Intravenous, Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Capsule - Oral, Capsule, Tablet, film coated, Tablet, film coated - Oral

Warnings

There are 20 known major drug interactions with Zyloprim.

Common Zyloprim Drug Interactions

Drug Name

Risk Level

Description

Didanosine

Major

The serum concentration of Didanosine can be increased when it is combined with Allopurinol.

Oteracil

Major

The therapeutic efficacy of Oteracil can be decreased when used in combination with Allopurinol.

Pegloticase

Major

The risk or severity of adverse effects can be increased when Allopurinol is combined with Pegloticase.

Abacavir

Minor

Allopurinol may decrease the excretion rate of Abacavir which could result in a higher serum level.

Aclidinium

Minor

Allopurinol may decrease the excretion rate of Aclidinium which could result in a higher serum level.

Zyloprim Toxicity & Overdose Risk

The lowest toxic dose of allopurinol in rats is 10mg/kg and 78mg/kg in mice. Studies on pregnant rats and rabbits have found that taking up to twenty times the normal human dose (about 5 mg/kg per day) does not cause fertility problems or harm to the fetus. However, a study on pregnant mice found that giving 50 or 100mg/kg of allopurinol could result in dead fetuses and malformations in the surviving fetuses. Allopurinol and its metabolite oxipurinol have been found in breastmilk. Cytogenic studies have

image of a doctor in a lab doing drug, clinical research

Zyloprim Novel Uses: Which Conditions Have a Clinical Trial Featuring Zyloprim?

560 active trials are in progress to analyze the potential of Zyloprim to ameliorate Kidney Disease, Chemotherapy-Related Issues and Metabolic Diseases.

Condition

Clinical Trials

Trial Phases

Chronic Kidney Disease (CKD)

28 Actively Recruiting

Phase 3, Not Applicable, Phase 2, Phase 1, Phase 4

failed previous allopurinol monotherapy

0 Actively Recruiting

Secondary gout

0 Actively Recruiting

Lymphoma, Non-Hodgkin

1 Actively Recruiting

Phase 1

Leukemia

1 Actively Recruiting

Not Applicable

Eczema

9 Actively Recruiting

Phase 2, Early Phase 1, Not Applicable, Phase 3

Lesch-Nyhan Syndrome

0 Actively Recruiting

Arthritis, Gouty

0 Actively Recruiting

Hyperuricemia

0 Actively Recruiting

Chemotherapy

4 Actively Recruiting

Phase 1, Phase 3, Not Applicable

female patients with daily uric acid excretion that exceeds 750 mg/day

0 Actively Recruiting

Kidney Calculi

0 Actively Recruiting

Metabolic Diseases

1 Actively Recruiting

Not Applicable

Hyperuricemia

3 Actively Recruiting

Phase 3, Phase 1

Urinary Bladder Calculi (disorder)

0 Actively Recruiting

Primary Gout

0 Actively Recruiting

Gout Flares

1 Actively Recruiting

Phase 2

Symptomatic

0 Actively Recruiting

Zyloprim Reviews: What are patients saying about Zyloprim?

5

Patient Review

10/13/2008

Zyloprim for High Amount of Uric Acid in the Blood

Allopurinol has been fantastic in keeping my uric acid levels down. I haven't had a gout attack in years!

5

Patient Review

9/5/2009

Zyloprim for Gout

I've been taking this medication for around 15 years to help with my gout, and it's always worked well. However, I'm now experiencing numbness in my fingers and toes, which is making everyday tasks more difficult.

5

Patient Review

1/2/2009

Zyloprim for Uric Acid Kidney Stones

I was content with this medication, until I found out that the FDA is approving a new drug and discontinuing this one. What's the reasoning behind this sudden change?

5

Patient Review

7/18/2009

Zyloprim for Gout

I'm so thankful for this pill because it always helps me when I get gout. It's really painful, and the brand name medication always makes it worse.

5

Patient Review

4/16/2009

Zyloprim for Gout

Allopurinol has been a life-saver for me. Gout used to be a constant problem, but since I've been taking this medication, I haven't had any issues at all.

5

Patient Review

10/20/2008

Zyloprim for Gout

It's been over a decade since I've had any problems with gout, and before that it was a regular occurrence. This treatment has been amazing in preventing pain.

5

Patient Review

4/2/2010

Zyloprim for Inflammation of the Joints due to Gout

This drug was a complete game-changer for me. The pain I was experiencing before hand was absolutely unbearable and caused me to miss work frequently. After being on this medication for six years, I experienced zero negative side effects. Not only that, but the medication allowed me to get rid of my crutches entirely!

5

Patient Review

10/14/2011

Zyloprim for Gout

I've been on allopurinol for five years now and it's really helped me. Recently, though, I was diagnosed with renal cell carcinoma. Has anyone else had a similar experience?

5

Patient Review

10/26/2008

Zyloprim for Gout

I've only been on this drug for three months, but I'm already really pleased with it.

4.3

Patient Review

12/13/2013

Zyloprim for Gout

This drug was effective in treating my gout and I saw results within a few days. However, I started experiencing tightness and tingling in my feet which has progressed over time. I went to see several different doctors but they were unable to diagnose the problem. After doing some research, I discovered that this could be a side effect of the allopurinol so I stopped taking it and the symptoms have gone away.

4

Patient Review

11/27/2007

Zyloprim for Gout

Zyloprim is a well-known and effective drug for treating gout. It's affordable, which is great.

3.7

Patient Review

7/27/2009

Zyloprim for High Amount of Uric Acid in the Blood

The medication caused me to feel nauseous for most of the day.

3.3

Patient Review

3/8/2012

Zyloprim for Inflammation of the Joints due to Gout

I found that this medication made me drowsy when taken with Sulindac 200mg. I was using it to treat a swollen knee and gout.

2.3

Patient Review

9/3/2021

Zyloprim for Inflammation of the Joints due to Gout

I have been taking zyloprim for a long time, but now that they've changed the color of the tablet to pink, I'm experiencing severe pain in my legs and shoulders. I can only move slowly and with great difficulty.

2

Patient Review

5/27/2011

Zyloprim for Gout

I have been taking allopurinol for about four months now and, during that time, I have experienced the most severe and longest-lasting attacks. Prior to taking the drug, my attacks occurred about once every two months and were usually a result of dietary slip-ups; however, since starting this medication, I have had pain for weeks at a time despite following my diet closely. Given the number of positive reviews for this treatment, I am surprised that it has not worked better for me.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zyloprim

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the drug Zyloprim used for?

"Allopurinol is a medication used to treat gout, certain types of kidney stones, and to prevent increased uric acid levels in cancer patients undergoing chemotherapy. Increased uric acid levels in these patients is caused by the release of uric acid from the cancer cells that are dying."

Answered by AI

Is Zyloprim the same as allopurinol?

"Allopurinol decreases the amount of uric acid produced by the body, which can prevent gout and kidney issues. It is sold under the brand names Zyloprim and Aloprim."

Answered by AI

When should Zyloprim be given?

"The recommended dosage for Allopurinol is one tablet taken once daily, preferably after a meal. To help your body eliminate uric acid, it is important to drink plenty of water throughout the day. Allopurinol should be taken with a full glass of water."

Answered by AI

What are the side effects of Zyloprim?

"drowsiness, headache, diarrhea, vomiting, stomach discomfort, changes in your sense of taste, muscle pain."

Answered by AI

Clinical Trials for Zyloprim

Image of UPMC Hillman Cancer Center in Pittsburgh, United States.

Mobile App for Cancer

18+
All Sexes
Pittsburgh, PA

The goal of this study is to determine whether a mobile application that combines real-time sensor data and patient-reported symptoms to trigger care-team contact recommendations is feasible and beneficial for patients receiving chemotherapy. The main questions it aims to answer are: * Is the mobile application feasible and acceptable to patients? * Do the alerts and guidance improve symptom management, quality of life, and engagement with the care team during treatment? Participants will: * Complete a demographic questionnaire at the beginning of the study and quality-of-life and health questionnaires at the beginning, midpoint, and end of study. * Complete daily symptom ratings via study application. * Wear a Fitbit activity tracker for 90 days. * At the end of the study, complete a semi-structured interview to provide feedback on the study. * Optional: At the beginning and end of the study, complete an in-person physical function assessment measuring balance (Short Physical Performance Battery).

Waitlist Available
Has No Placebo

UPMC Hillman Cancer Center

Carissa A Low

Have you considered Zyloprim clinical trials?

We made a collection of clinical trials featuring Zyloprim, we think they might fit your search criteria.
Go to Trials

Have you considered Zyloprim clinical trials?

We made a collection of clinical trials featuring Zyloprim, we think they might fit your search criteria.
Go to Trials
Image of South Florida Research Institute in Lauderdale Lakes, United States.

Mezagitamab for Berger's Disease

18+
All Sexes
Lauderdale Lakes, FL

Immunoglobulin A nephropathy (IgAN) is a kidney condition. It happens when the body's immune system creates groups of proteins (called immune complexes) that build-up in the kidneys causing swelling (inflammation). Over time, this inflammation may lead to kidney damage and cause the kidneys to no longer work properly. The main aim of this study is to check how well mezagitamab changes protein levels in the urine (proteinuria) compared to placebo in adults with primary IgAN. A placebo looks like medicine but doesn't have any active ingredients in it. Other aims are to check how safe mezagitamab is and how well participants with primary IgAN can tolerate it compared to placebo, and to find out if and how well mezagitamab continues to maintain kidney function over the long term compared to placebo. Participants will be placed in 1 of the 2 treatment groups; the main group and the open-label group. In the main group, participants will be placed in 1 of the 2 treatment groups by chance (either mezagitamab or placebo) at a 2:1 ratio. This means that out of 3 participants, 2 will receive mezagitamab and 1 will receive placebo. The participants will receive either mezagitamab or placebo for almost half a year in two 1-year cycles. They will be observed for another half year in each 1-year cycle and will have check-ups about every month during this time. In the open-label group, a small number of participants who have lower levels of protein in their urine or have kidneys that do not filter the blood well, will receive mezagitamab treatment. This will include participants who have previously received mezagitamab in another study, TAK-079-1006. Every participant will receive mezagitamab in the same way as those in the main group receiving mezagitamab. During the study, participants will visit their study clinic several times.

Phase 3
Recruiting

South Florida Research Institute (+20 Sites)

Study Director

Takeda

Image of PAREXEL International - Early Phase Clinical Unit Baltimore in Baltimore, United States.

NNC4004-0002 for High Uric Acid

35 - 75
All Sexes
Baltimore, MD

This study will evaluate an investigational drug called NNC4004-0002. "Investigational" means NNC4004-0002 has not been approved for sale/ for clinical use or for the use described in this study/ by any regulatory authority. Its use in this study is experimental. This will be the first time that NNC4004-0002 will be given to human. This study will be testing the ability of the study medicine to lower serum uric acid. The main aim of this study will be to see if the new study medicine is safe and tolerated by the body after a single dose of study medicine in adults with asymptomatic hyperuricemia. Participants will either get NNC4004-0002 (the study medicine), or saline. Which treatment the participant get will be decided by chance. The participant will get the medicine as an injection under their skin. Depending on the dose they will receive, participant may need more than one injection. The study will last for about 19 months in total. The participant will take part in the study for about 7 months. Participant will have approximately 14 visits to the clinic and one of them will be a 4 night in-house stay.

Phase 1
Recruiting

PAREXEL International - Early Phase Clinical Unit Baltimore (+2 Sites)

Clinical Transparency (dept. 2834)

Novo Nordisk A/S

Have you considered Zyloprim clinical trials?

We made a collection of clinical trials featuring Zyloprim, we think they might fit your search criteria.
Go to Trials